It’s Time to Give NERLYNX a Second Look: A Case-Based Discussion on Reducing Recurrence in HER2+ eBC¹-³

PRESENTED BY: SURESH RATNAM, MD, FACP
TEXAS ONCOLOGY MCALLEN
MCALLEN, TX

PROGRAM HOST: KARA GESSINGER
(574) 532-0222

LIVE PROGRAM INFORMATION: WEDNESDAY, JUNE 28, 2023 at 6:00 PM
HYDE PARK PRIME STEAKHOUSE
201 SOUTH OLD WOODWARD AVENUE
BIRMINGHAM, MI

Program Featuring:
- Clinical case studies based on actual NERLYNX patients with HER2+ eBC with and without a pCR
- Final efficacy results from the pivotal ExteNET trial: primary endpoint, descriptive analyses of iDFS, OS, and CNS
- Safety information: an evolved approach using dose escalation

PLEASE REGISTER ONLINE AT: [http://pumareg.tsgmeded.com](http://pumareg.tsgmeded.com) LSC or Event Code: 53883
Please register by June 22, 2023 as space is limited.
Registration assures your spot and assists Puma Biotechnology with holding efficient programs.

INDICATIONS AND USAGE:
NERLYNX® (neratinib) tablets, for oral use, is a kinase inhibitor indicated:
- As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
- In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

SELECT IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS: The most common adverse reactions (reported in ≥ 5% of patients) were:
- NERLYNX as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.
- NERLYNX in combination with capecitabine: diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.

New Jersey, Minnesota, Vermont, the Department of Defense, and the Department of Veterans Affairs have restrictions on receiving in-kind benefits (e.g., meals, paid parking) at company-sponsored events. For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Puma Biotechnology policies may restrict you from consuming any portion of the Puma Biotechnology-sponsored meal at this program or from receiving any other in-kind benefit from Puma Biotechnology (e.g., paid parking) in connection with the program.

This program is sponsored by Puma Biotechnology, Inc. This is not an independent educational program, and no CME credits will be provided.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; HER2 = human epidermal growth factor receptor 2; iDFS = invasive disease-free survival; CNS = central nervous system.

Please see additional Important Safety Information on next page and accompanying Full Prescribing Information including Patient Information.
NERLYNX® (neratinib) tablets, for oral use

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

● Diarrhea: Manage diarrhea through either NERLYNX dose escalation or loperamide prophylaxis. If diarrhea occurs despite recommended prophylaxis, treat with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold NERLYNX in patients experiencing severe and/or persistent diarrhea. Permanently discontinue NERLYNX in patients experiencing Grade 4 diarrhea or Grade ≥2 diarrhea that occurs after maximal dose reduction.

● Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.

● Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS: The most common adverse reactions (reported in ≥ 5% of patients) were:

● NERLYNX as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.

● NERLYNX in combination with capecitabine: diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

● Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. Separate NERLYNX by at least 2 hours before or 10 hours after H₂-receptor antagonists. Or separate NERLYNX by at least 3 hours after antacids.

● Strong CYP3A4 inhibitors: Avoid concomitant use.

● P-gp and moderate CYP3A4 dual inhibitors: Avoid concomitant use.

● Strong or moderate CYP3A4 inducers: Avoid concomitant use.

● Certain P-gp substrates: Monitor for adverse reactions of P-gp substrates for which minimal concentration change may lead to serious adverse reactions when used concomitantly with NERLYNX.

USE IN SPECIFIC POPULATIONS:

● Lactation: Advise women not to breastfeed.

ALT = alanine aminotransferase; AST = aspartate aminotransferase; HER2 = human epidermal growth factor receptor 2.

Please see accompanying Full Prescribing Information including Patient Information.

References: